Theranos founder Elizabeth Holmes was convicted of four counts of fraud in a case that’s viewed as a landmark test of Silicon Valley startup culture.

The trial of the Theranos founder is seen as a bellwether for Silicon Valley.

It's become a cautionary tale for biotech investors. Are they heeding it?

The settlement comes two years after the SEC began looking into claims at Theranos that it had developed potentially revolutionary blood-testing technology.

From $4.5 billion to nothing.

The Wall Street Journal reports tens of thousands of corrections were issued.